All the statements are True regarding Selexipag except?
Selexipag is an orally active, Selective IP receptor agonist(Prostacyclin Receptor Agonist) . Selexipag has shown to reduce Morbidity and Moality in patients with Pulmonary HT . A/E : similar to those of PGI2 analogues and include headache, jaw pain, nausea, dizziness, flushing, nasopharyngitis and vomiting. Adverse effects appear to be more common when the drug is taken while fasting . MOA :
Selective IP receptor antagonist
Prostacyclin receptor agonist
Used in Pulmonary Hypeension
Adverse effects of Selexipag are similar to those of PGI2 analogues
Respiratory System